Herein, we report the synthesis of a novel class of substituted androst[17,16- b]
pyridines (pyridosteroids) from the reaction of β-formyl enamides with
alkynes in high yields. The optimized reaction protocol was extended to acyclic and cyclic β-formyl enamides to afford nonsteroidal
pyridines. Cell survival assay of all compounds were carried against
prostate cancer PC-3 cells wherein 3-hydroxy-5-en-2',3'-dicarbethoxy-androst[17,16-
b]pyridine showed the highest cytotoxic activity. Phase contrast microscopy and flow cytometry studies exhibited marked morphological features characteristic of apoptosis in 3-hydroxy-5-en-2',3'-dicarbethoxy-androst[17,16-
b]pyridine and
abiraterone treated PC-3 cells. The treatment of 3-hydroxy-5-en-2',3'-dicarbethoxy-androst[17,16-
b]pyridine induces G2/M phase cell cycle arrest in
prostate cancer PC-3 cells. Enhancement of apoptotic inductions of PC-3 cells by 3-hydroxy-5-en-2',3'-dicarbethoxy-androst[17,16-
b]pyridine and
abiraterone through the activation of caspases-6, -7, and -8 pathways were supported by qRT-PCR. In silico study of the compound 3-hydroxy-5-en-2',3'-dicarbethoxy-androst[17,16-
b]pyridine showed stable and promising interaction with the key
caspase proteins. Our studies revealed that the pyridosteroid 3-hydroxy-5-en-2',3'-dicarbethoxy-androst[17,16-
b]pyridine, bearing pyridine-2,3-dicarbethoxy pharmacophore, facilitated initiation of
caspase-8 and activates downstream effectors
caspase-6 and
caspase-7 and thereby triggering apoptosis of PC-3
cancer cells.